PMID- 34141790
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210619
IS  - 2307-8960 (Print)
IS  - 2307-8960 (Electronic)
IS  - 2307-8960 (Linking)
VI  - 9
IP  - 17
DP  - 2021 Jun 16
TI  - Diagnosis and treatment of pediatric anaplastic lymphoma kinase-positive large 
      B-cell lymphoma: A case report.
PG  - 4268-4278
LID - 10.12998/wjcc.v9.i17.4268 [doi]
AB  - BACKGROUND: Anaplastic lymphoma kinase-positive (ALK+) large B-cell lymphoma 
      (LBCL) is a rare type of lymphoma with high invasiveness and rapid progression. 
      It occurs in all age groups, but is extremely rare in children. The lesions 
      mainly involve the lymph nodes and may present with extra-nodal involvement. 
      Response to conventional chemotherapies and local radiotherapy is poor, with a 
      5-year overall survival of less than 40%. Recently, the use of ALK inhibitors for 
      the treatment of this disease has been reported. CASE SUMMARY: We present a case 
      of a 12-year-old boy diagnosed with ALK+LBCL. The patient had a 2-mo medical 
      history of a calvarial mass, extensive systemic involvement, and positive bone 
      marrow clathrin heavy chain (CLTC)-ALK fusion gene. Complete remission 1 (CR1) 
      was achieved using the modified LMB89 Group C regimen followed by autologous stem 
      cell transplantation. The patient relapsed 3 mo later. He then achieved CR2 with 
      three short courses of chemotherapy (COP, reduced-dose ICE, low-dose Ara-c+VP16) 
      and continuous alectinib targeted therapy. Afterward, allogeneic hematopoietic 
      stem cell transplantation (allo-HSCT) was performed. At 16 mo after the 
      allo-HSCT, the patient was still in CR2. CONCLUSION: The modified LMB89 Group C 
      regimen and ALK inhibitors are effective. Allo-HSCT should be performed after 
      remission.
CI  - (c)The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights 
      reserved.
FAU - Zhang, Meng
AU  - Zhang M
AD  - Beijing Key Laboratory of Pediatric Hematology Oncology, National Discipline of 
      Pediatrics, Ministry of Education, MOE Key Laboratory of Major Diseases in 
      Children, Hematology Oncology Center, Beijing Children's Hospital, Capital 
      Medical University, National Center for Children's Health, Beijing 100045, China.
FAU - Jin, Ling
AU  - Jin L
AD  - Beijing Key Laboratory of Pediatric Hematology Oncology, National Discipline of 
      Pediatrics, Ministry of Education, MOE Key Laboratory of Major Diseases in 
      Children, Hematology Oncology Center, Beijing Children's Hospital, Capital 
      Medical University, National Center for Children's Health, Beijing 100045, China.
FAU - Duan, Yan-Long
AU  - Duan YL
AD  - Beijing Key Laboratory of Pediatric Hematology Oncology, National Discipline of 
      Pediatrics, Ministry of Education, MOE Key Laboratory of Major Diseases in 
      Children, Hematology Oncology Center, Beijing Children's Hospital, Capital 
      Medical University, National Center for Children's Health, Beijing 100045, China.
FAU - Yang, Jing
AU  - Yang J
AD  - Beijing Key Laboratory of Pediatric Hematology Oncology, National Discipline of 
      Pediatrics, Ministry of Education, MOE Key Laboratory of Major Diseases in 
      Children, Hematology Oncology Center, Beijing Children's Hospital, Capital 
      Medical University, National Center for Children's Health, Beijing 100045, China.
FAU - Huang, Shuang
AU  - Huang S
AD  - Beijing Key Laboratory of Pediatric Hematology Oncology, National Discipline of 
      Pediatrics, Ministry of Education, MOE Key Laboratory of Major Diseases in 
      Children, Hematology Oncology Center, Beijing Children's Hospital, Capital 
      Medical University, National Center for Children's Health, Beijing 100045, China.
FAU - Jin, Mei
AU  - Jin M
AD  - Beijing Key Laboratory of Pediatric Hematology Oncology, National Discipline of 
      Pediatrics, Ministry of Education, MOE Key Laboratory of Major Diseases in 
      Children, Hematology Oncology Center, Beijing Children's Hospital, Capital 
      Medical University, National Center for Children's Health, Beijing 100045, China.
FAU - Zhu, Guang-Hua
AU  - Zhu GH
AD  - Beijing Key Laboratory of Pediatric Hematology Oncology, National Discipline of 
      Pediatrics, Ministry of Education, MOE Key Laboratory of Major Diseases in 
      Children, Hematology Oncology Center, Beijing Children's Hospital, Capital 
      Medical University, National Center for Children's Health, Beijing 100045, China.
FAU - Gao, Chao
AU  - Gao C
AD  - Beijing Key Laboratory of Pediatric Hematology Oncology, National Discipline of 
      Pediatrics, Ministry of Education, MOE Key Laboratory of Major Diseases in 
      Children, Hematology Oncology Center, Beijing Children's Hospital, Capital 
      Medical University, National Center for Children's Health, Beijing 100045, China.
FAU - Liu, Yi
AU  - Liu Y
AD  - Beijing Key Laboratory of Pediatric Hematology Oncology, National Discipline of 
      Pediatrics, Ministry of Education, MOE Key Laboratory of Major Diseases in 
      Children, Hematology Oncology Center, Beijing Children's Hospital, Capital 
      Medical University, National Center for Children's Health, Beijing 100045, China.
FAU - Zhang, Nan
AU  - Zhang N
AD  - Beijing Key Laboratory of Pediatric Hematology Oncology, National Discipline of 
      Pediatrics, Ministry of Education, MOE Key Laboratory of Major Diseases in 
      Children, Hematology Oncology Center, Beijing Children's Hospital, Capital 
      Medical University, National Center for Children's Health, Beijing 100045, China.
FAU - Zhou, Chun-Ju
AU  - Zhou CJ
AD  - Department of Pathology, Beijing Children's Hospital, Capital Medical University, 
      National Center for Children's Health, Beijing 100045, China.
FAU - Gao, Zi-Fen
AU  - Gao ZF
AD  - Department of Pathology, Peking University Third Hospital, Beijing 100191, China.
FAU - Zheng, Qin-Long
AU  - Zheng QL
AD  - Laboratory of Molecular Diagnostics, Department of Pathology and Laboratory 
      Medicine, Beijing Boren Hospital, Beijing 100070, China.
FAU - Chen, Dong
AU  - Chen D
AD  - Division of Hematopathology, Mayo Clinic, Rochester, MN 55905, United States.
FAU - Zhang, Yong-Hong
AU  - Zhang YH
AD  - Beijing Key Laboratory of Pediatric Hematology Oncology, National Discipline of 
      Pediatrics, Ministry of Education, MOE Key Laboratory of Major Diseases in 
      Children, Hematology Oncology Center, Beijing Children's Hospital, Capital 
      Medical University, National Center for Children's Health, Beijing 100045, China. 
      yhzhang58@hotmail.com.
LA  - eng
PT  - Case Reports
PL  - United States
TA  - World J Clin Cases
JT  - World journal of clinical cases
JID - 101618806
PMC - PMC8173411
OTO - NOTNLM
OT  - Alectinib
OT  - Anaplastic lymphoma kinase-positive large B-cell lymphoma
OT  - CLTC-ALK
OT  - Case report
OT  - Hematopoietic stem cell transplantation
OT  - PGS1-CLTC
OT  - Pediatric
COIS- Conflict-of-interest statement: The authors declare that they have no conflicts 
      of interest.
EDAT- 2021/06/19 06:00
MHDA- 2021/06/19 06:01
PMCR- 2021/06/16
CRDT- 2021/06/18 06:48
PHST- 2020/12/31 00:00 [received]
PHST- 2021/03/15 00:00 [revised]
PHST- 2021/03/29 00:00 [accepted]
PHST- 2021/06/18 06:48 [entrez]
PHST- 2021/06/19 06:00 [pubmed]
PHST- 2021/06/19 06:01 [medline]
PHST- 2021/06/16 00:00 [pmc-release]
AID - 10.12998/wjcc.v9.i17.4268 [doi]
PST - ppublish
SO  - World J Clin Cases. 2021 Jun 16;9(17):4268-4278. doi: 10.12998/wjcc.v9.i17.4268.